UDSKRIFT 🔗
WEBVTT
00:00:00.080 --> 00:00:04.160
Scientists protected glaucoma nerve cells without lowering eye pressure.
00:00:04.400 --> 00:00:07.679
Could mitochondria become the next treatment target?
00:00:07.919 --> 00:00:18.960
Short answer: possibly, but the new study is a promising prevention result, not yet proof that mitochondrial treatment can restore vision after glaucoma damage is established.
00:00:19.199 --> 00:00:26.079
The study at the center of this question was first published in Advanced Science on October 18, 2026.
00:00:26.320 --> 00:00:35.280
Researchers used adeno-associated virus serotype 2 to increase akinase anchoring protein 1, or ACAP-1, in the retina.
00:00:35.520 --> 00:00:46.719
Treated mice retained more retinal ganglion cells, had better electrical responses, and showed stronger tracer labeling along the projection to the brain, even while their eye pressure remained elevated.
00:00:46.880 --> 00:00:50.880
The results support the idea of pressure-independent neuroprotection.
00:00:51.119 --> 00:00:58.719
They do not show that treatment lowered pressure, nor do they show that it rescued neurons after damage was already measurable.
00:00:59.039 --> 00:01:02.640
The October 2026 Advanced Science Paper.
00:01:02.960 --> 00:01:04.799
That distinction matters.
00:01:05.040 --> 00:01:10.400
A treatment given before pressure injury may prevent cells from becoming dysfunctional or dying.
00:01:10.560 --> 00:01:20.480
A treatment given after visual function has declined would have to do something more: restore function in living but impaired cells, rebuild lost connections, or both.
00:01:20.799 --> 00:01:23.359
The study did not test that harder question.
00:01:23.519 --> 00:01:31.519
What ACAP1 does, ACAP1 is a signaling scaffold, a protein that helps hold other signaling proteins in a useful place.
00:01:31.760 --> 00:01:37.120
It is normally attached to the outer membrane of mitochondria, the cell's energy-producing structures.
00:01:37.439 --> 00:01:40.799
ACAP1 is not itself an energy-producing enzyme.
00:01:41.040 --> 00:01:50.319
Its importance is that it helps organize signals near the mitochondrion, where those signals can influence mitochondrial shape, stress responses, and survival.
00:01:50.719 --> 00:01:54.640
One important partner is protein kinase A, or PKA.
00:01:54.879 --> 00:02:00.159
ACAP1 can anchor PKA close to mitochondrial targets, including the fission protein DRP1.
00:02:00.560 --> 00:02:11.520
PKA-mediated phosphorylation of DRP1 at a particular site, serine 637 in the mouse numbering used in this work, usually makes DRP1 less able to drive mitochondrial fission.
00:02:11.680 --> 00:02:19.439
The calcium-sensitive enzyme calcinurin can remove that phosphate, which can favor DRP1 activity and mitochondrial division.
00:02:19.680 --> 00:02:34.319
Earlier laboratory work found that loss of ACAP1 in mouse retina was associated with lower DRP1 phosphorylation, more fragmented mitochondria, abnormal respiratory chain proteins, and signs of oxidative and cell death stress.
00:02:34.560 --> 00:02:39.439
The earlier retinal ECAP1 study, mitochondria need both fusion and fission.
00:02:39.599 --> 00:02:43.439
Fusion can help mitochondria share contents and maintain function.
00:02:43.680 --> 00:02:51.120
Fission helps separate damaged parts, support mitochondrial transport, and allow quality control processes such as mitophagy.
00:02:51.680 --> 00:02:58.240
The goal is not simply more fusion, it is a healthy balance that changes appropriately with a cell's needs.
00:02:58.560 --> 00:03:07.599
ACAP1 is also linked to OPA1, a protein on the inner mitochondrial membrane that helps govern fusion and the structure of the folds called CRISTAe.
00:03:07.840 --> 00:03:11.919
But the new study did not show that ACAP1 physically binds OPA1.
00:03:12.319 --> 00:03:16.319
It showed that OPA1 levels changed along with ACAP1 treatment.
00:03:16.479 --> 00:03:25.360
The direct mechanistic case is stronger for the ACAP1-PKA DRP1 relationship than for any direct ACAP1-OPA1 interaction.
00:03:25.599 --> 00:03:33.520
Mitochondria also helped manage cellular calcium and supply energy for processes such as nerve signaling and the release of neurotransmitters.
00:03:33.759 --> 00:03:42.080
It is therefore biologically plausible that mitochondrial stress could affect both calcium-sensitive signaling and synaptic performance.
00:03:42.319 --> 00:03:54.000
But in the new study, calcium handling was not directly measured, and the investigators did not establish that ACAP1's synaptic effects were caused by restoring a particular calcium pathway.
00:03:54.400 --> 00:04:03.759
The authors themselves note that they did not measure PKA catalytic activity, recruitment of PKA to mitochondria, or formation of the ACAP1 pKa complex.
00:04:04.000 --> 00:04:06.719
Is ACAP1 reduced in people with glaucoma?
00:04:06.960 --> 00:04:09.680
Not in the new October 2026 study.
00:04:09.919 --> 00:04:15.199
That study is based on mouse models and cultured retinal cells, not human donor retina.
00:04:15.280 --> 00:04:19.839
Its central experiments do not establish how ACAP1 changes in human glaucoma.
00:04:20.240 --> 00:04:24.160
There is, however, relevant human tissue evidence in a separate study.
00:04:24.399 --> 00:04:31.759
In a small postmortem series, ACAP1 staining was lower within retinal ganglion cell bodies from glaucoma donors.
00:04:32.160 --> 00:04:35.199
The overall retinal signal was not simply lower.
00:04:35.439 --> 00:04:43.439
A CAP1 staining was higher in some broader retinal measurements, apparently because ACAP1 was also increased in Miller glial cells.
00:04:43.680 --> 00:04:48.480
In other words, the answer depends on which cell type and which retinal region are measured.
00:04:48.720 --> 00:04:58.480
The human evidence is encouraging, but it is small, cross-sectional, and cannot tell whether the ACAP1 change caused degeneration or occurred in response to it.
00:04:58.720 -->
Load full transcript
00:05:01.360
Related study including human donor retina.
00:05:01.680 --> 00:05:08.720
Fact, a separate small human tissue study reports lower ACAP1 signal in glaucoma retinal ganglion cell bodies.
00:05:09.040 --> 00:05:10.240
Strong inference.
00:05:10.480 --> 00:05:19.279
A cap 1 may be relevant to human disease, but it is not yet established as a consistently reduced causal driver across glaucoma patients.
00:05:19.600 --> 00:05:27.519
What the October 2026 study actually did, the researchers used two mouse models and a set of cell culture experiments.
00:05:27.759 --> 00:05:33.279
The treatment was a viral vector carrying mouse ACAP1 under a broad cytomegalovirus promoter.
00:05:33.439 --> 00:05:36.480
The vector was not restricted to retinal ganglion cells.
00:05:36.639 --> 00:05:39.199
Other retinal cells could also receive it.
00:05:39.600 --> 00:05:45.439
DBA2J spontaneous glaucoma, DBA2J mice develop glaucoma as they age.
00:05:45.600 --> 00:05:51.600
The researchers injected the vector into the vitreous of five-month-old mice and assessed them at 10 months.
00:05:51.759 --> 00:05:59.839
Age-matched DBA2J GPNMB positive mice, which do not develop the same glaucoma phenotype, served as non-glaucomatous controls.
00:06:00.000 --> 00:06:08.879
Only DBA2J mice with recorded intraocular pressure between 20 and 35 mm of mercury were included in the glaucoma analyses.
00:06:09.040 --> 00:06:16.319
Across the screening cohort, 64 of 98 10-month-old DBA2J mice had confirmed pressure elevation.
00:06:16.560 --> 00:06:29.120
The methods report peak pressure averages of 21.5-4.5 mm of mercury in right eyes and 19.93.7 mm of mercury in left eyes for the glaucoma mouse cohort.
00:06:29.360 --> 00:06:34.639
These are not presented as the treatment versus control means for the specific vector comparison.
00:06:35.279 --> 00:06:46.000
The authors report that ACAT-1-treated DBA2J mice had more retinal ganglion cells in both middle and peripheral retinal regions than glaucoma mice given the null vector.
00:06:46.240 --> 00:07:01.279
More cholerotoxin B tracer labeling in the superior colliculus, a brain region receiving retinal input, higher pattern electroretinogram, and pattern visual evoke potential amplitudes, no improvement in pattern visual evoke potential latency.
00:07:01.680 --> 00:07:06.639
The vector increased retinal ACAT-1 and also increased pKa abundance.
00:07:06.800 --> 00:07:16.959
The paper reports the main outcomes as statistically significant, but the searchable article text does not give exact group means or percentage improvements for the plots.
00:07:17.199 --> 00:07:33.519
The figure legends supply sample sizes, 20 mice per group for the pressure panel, 9 to 18 retinas or mice for retinal ganglion cell counts, 10 mice per group for electrical responses, and 3 mice for the superior colliculous tracer analysis.
00:07:33.839 --> 00:07:36.560
Microbead-induced ocular hypertension.
00:07:36.800 --> 00:07:42.720
In the second model, beads were placed in the front of the eye to obstruct fluid outflow and raise pressure.
00:07:42.879 --> 00:07:50.000
The article's results section describes vector injection in three-month-old mice three weeks before the bead injection.
00:07:50.240 --> 00:07:56.959
The methods section, however, describes six-week-old mice being injected with vector before bead administration.
00:07:57.199 --> 00:08:01.360
This age discrepancy is an internal reporting inconsistency.
00:08:01.600 --> 00:08:04.000
It does not change the key timing point.
00:08:04.240 --> 00:08:07.920
The vector was given before ocular hypertension was induced.
00:08:08.079 --> 00:08:16.240
The bead model produced sustained intraocular pressure in the reported range of 20 to 30 millimeters of mercury for at least eight weeks.
00:08:16.480 --> 00:08:23.759
Pressure monitoring did not show a statistically significant difference between ACAP1 vector and nullvector groups.
00:08:24.079 --> 00:08:39.759
Compared with nullvector mice, ACAP 1 treated mice retained more retinal ganglion cells, had better pattern electroretinogram and pattern visual evoked potential amplitudes, and had shorter, more normalized pattern visual evoked potential latency.
00:08:40.000 --> 00:08:51.039
The figure legend reports 12 to 14 mice per group for pressure monitoring and electrical responses, and 7 to 10 retinal hole mounts per group for retinal ganglion cell counts.
00:08:51.840 --> 00:08:56.639
The researchers also tested pressure-stressed retinal ganglion cells in culture.
00:08:56.799 --> 00:09:04.399
Cells were transduced with the vector before exposure to elevated hydrostatic pressure or paraquat, an oxidative stressor.
00:09:04.639 --> 00:09:09.519
ACAT-1 improved cell viability and oxygen consumption measures under stress.
00:09:09.679 --> 00:09:16.000
This is useful mechanistic support, but it is another pre-injury treatment experiment, not a rescue experiment.
00:09:16.480 --> 00:09:19.440
What the paper does and does not quantify.
00:09:20.000 --> 00:09:34.159
The paper reports terms on statistical significance for many plotted outcomes, but the full text prose and figure legends do not provide exact numerical means, standard deviations, or percentage changes for most of the outcomes listed below.
00:09:34.320 --> 00:09:38.720
I have not inferred precise bar heights from figures or invented values.
00:09:38.960 --> 00:09:43.360
For the full table, please open this article on VisualFieldTest.com.
00:09:43.600 --> 00:09:51.840
The full study gives the sample sizes and qualitative results, but not an accessible numeric table of all plotted outcome values.
00:09:52.080 --> 00:09:56.799
That limits independent estimation of effect size and clinical relevance.
00:09:57.200 --> 00:10:07.039
The article also reports that some ultrastructural analyses counted many mitochondria or synaptic structures, but drew those structures from only two mice per group.
00:10:07.279 --> 00:10:15.120
Such measurements
are informative for cell biology, but the number of mitochondria is not a substitute for the number of independent animals.
00:10:15.759 --> 00:10:19.600
How convincing is the evidence for pressure-independent protection?
00:10:20.240 --> 00:10:22.720
It is a meaningful preclinical result.
00:10:23.200 --> 00:10:35.039
But pressure independent should be read as the observed protection was not accompanied by a detected pressure reduction, not as proof that every aspect of pressure exposure was perfectly matched.
00:10:35.440 --> 00:10:37.679
The case is strengthened by three features.
00:10:37.840 --> 00:10:45.120
Two different glaucoma models showed better retinal ganglion cell survival or visual responses with ACAP1 treatment.
00:10:45.360 --> 00:10:54.080
In the microbead model, pressure was monitored and was reported as not significantly different between the ACAP1 and null vector treatment groups.
00:10:54.480 --> 00:11:03.759
In the DBA2J model, glaucoma mice were selected from a pressure-elevated range, and the paper does not report pressure lowering by the vector.
00:11:04.080 --> 00:11:06.080
But important qualifications remain.
00:11:06.320 --> 00:11:11.120
A non-significant difference is not the same as proof of equivalent pressure exposure.
00:11:11.360 --> 00:11:16.559
The study does not establish equivalence using a pre-specified equivalence margin.
00:11:16.799 --> 00:11:30.159
Repeated pressure measurements are more informative than a single reading, but the paper does not demonstrate a complete high-resolution comparison of each eye's cumulative pressure burden, including nighttime or short-lived peaks.
00:11:30.879 --> 00:11:36.000
In the DBA2J experiment, the reported pressure range is an inclusion criterion.
00:11:36.240 --> 00:11:41.840
The paper does not provide detailed cumulative pressure exposure for each treatment group.
00:11:42.240 --> 00:11:48.159
The study's separate ACAT-1 deficient mouse experiment is less clean as causal evidence.
00:11:48.320 --> 00:11:57.600
Those mice had slightly higher pressure than wild type mice, and the authors acknowledge that this could have contributed to worse pattern electroretinogram responses.
00:11:57.919 --> 00:12:02.240
Were the investigators blinded and were the samples large enough?
00:12:02.480 --> 00:12:06.720
The animals were randomly assigned to experimental and control groups.
00:12:07.039 --> 00:12:15.279
The paper explicitly says that sampling, segmentation, and quantification of the serial block face electron microscopy data were blinded.
00:12:15.440 --> 00:12:26.960
In the accessible report, I did not find a comparable clear statement that the pressure measurements, electrical response assessments, retinal ganglion cell counts, or other key outcomes were blinded.
00:12:27.200 --> 00:12:28.960
That is a reporting gap.
00:12:29.200 --> 00:12:32.720
It does not prove that those assessments were unblinded.
00:12:32.879 --> 00:12:38.159
The sample sizes are reasonable for an initial mouse study, but uneven in strength.
00:12:38.399 --> 00:12:46.240
Pressure and electrical response groups often included around 10 to 14 animals, while many biochemical measures used only 3 to 8.
00:12:46.399 --> 00:12:49.600
Some ultrastructural conclusions used two animals per group.
00:12:49.759 --> 00:12:58.879
The study is also from one research program, and the two mouse models do not replace replication by independent laboratories or testing in a large animal.
00:12:59.440 --> 00:13:00.639
Strong inference.
00:13:00.799 --> 00:13:07.279
The study supports the conclusion that AKP1 can protect the retina without an observed reduction in pressure.
00:13:07.600 --> 00:13:08.159
Fact.
00:13:08.559 --> 00:13:16.960
It does not prove that cumulative pressure exposure was identical in every treated and untreated animal, and it does not provide human efficacy evidence.
00:13:17.200 --> 00:13:20.080
Which parts of the proposed mechanism were demonstrated?
00:13:20.320 --> 00:13:36.320
The proposed chain is elevated pressure, mitochondrial stress, lower ACAP1, abnormal DRP1 activity and fission, weaker energy production, synaptic dysfunction, inflammation and complement activation, retinal ganglion cell dysfunction and death.
00:13:36.480 --> 00:13:41.279
The new study supports portions of this chain, but it does not demonstrate every arrow.
00:13:41.519 --> 00:13:43.519
Elevated pressure and ACAP1.
00:13:44.000 --> 00:13:50.639
The DBA2J glaucoma model showed lower retinal ACAP1 alongside pressure elevation and injury.
00:13:50.799 --> 00:13:58.000
The microbed model and stressed cell experiments support a relationship between glaucomatous stress and retinal vulnerability.
00:13:58.240 --> 00:14:07.519
But the experiments do not show that pressure directly lowers ACAP1 by one isolated mechanism, or that all the subsequent changes are caused by ACAP1 loss.
00:14:07.759 --> 00:14:12.399
Evidence grade association in vivo, not a complete cause and effect test.
00:14:12.639 --> 00:14:16.080
ACAP1, DRP1, and mitochondrial dynamics.
00:14:16.320 --> 00:14:29.279
With ACAP1 restoration, the authors found higher DRP1 phosphorylation at serine 637, lower total DRP1, and no detectable change in phosphorylation at serine 616.
00:14:29.519 --> 00:14:37.759
They also found more OPA-1, including more of its long form, while mitofusin 1 and mitochusin 2 protein levels were not changed.
00:14:38.000 --> 00:14:43.679
These findings are consistent with a shift away from excessive fission and toward mitochondrial stability.
00:14:43.840 --> 00:14:50.799
In pressure-stressed cultured retinal ganglion cells, ACAP1 also improved respiration and mitochondrial shape.
00:14:50.960 --> 00:15:00.320
However, the study did not use a DRP-1 mutant that could no longer be phosphorylated at the relevant site, or an ACAP1 version unable to anchor pKa.
00:15:00.480 --> 00:15:06.399
It therefore does not establish that DRP-1 phosphorylation is required for ACAP1's
protective effect.
00:15:06.639 --> 00:15:13.360
Evidence grade, strong preclinical support for a relationship, incomplete proof of the precise causal route.
00:15:13.600 --> 00:15:16.159
Energy production and oxidative stress.
00:15:16.399 --> 00:15:24.080
In cultured cells, ACAP1 improved basal, maximal, and adenosine triphosphate-linked oxygen consumption under pressure stress.
00:15:24.240 --> 00:15:28.000
Under paraquat stress, it reduced mitochondrial superoxide.
00:15:28.159 --> 00:15:33.360
In retina, it changed respiratory chain protein levels and stress-associated markers.
00:15:33.600 --> 00:15:41.200
But the study's estimate of adenosine triphosphate production in some analyses came from a model using mitochondrial ultrastructure.
00:15:41.360 --> 00:15:45.919
It was not a direct in vivo measurement of energy supply to retinal ganglion cells.
00:15:46.159 --> 00:15:54.000
Evidence grade, direct respiratory measurements in cultured cells, indirect or proxy measures for several in vivo energy claims.
00:15:54.240 --> 00:15:56.159
Synaptic changes in inflammation.
00:15:56.320 --> 00:16:08.240
The paper found lower phosphorylation of calcium calmodulin-dependent kinase 2 and synapsin after ACAT-1 treatment, preservation of synaptophacin, and improved postsynaptic density protein 95.
00:16:08.639 --> 00:16:16.720
It also found lower C1Q, IBA1, gliofibrillary acidic protein, and inflammatory transcripts in treated retina.
00:16:16.960 --> 00:16:20.240
These are important observations, but they are associations.
00:16:20.399 --> 00:16:27.600
The study did not show that changing C1Q or the synaptic proteins was necessary for the retinal ganglion cell benefit.
00:16:27.840 --> 00:16:36.879
The authors also acknowledged that lower inflammatory markers could be a consequence of less retinal injury rather than a direct anti-inflammatory effect of ACAP-1.
00:16:38.080 --> 00:16:40.879
Retinal ganglion cell function and death?
00:16:41.120 --> 00:16:45.360
The researchers measured retinal ganglion cell counts and electrical responses.
00:16:45.600 --> 00:16:49.919
Treatment groups did better than null vector groups at the study endpoints.
00:16:50.240 --> 00:17:02.320
But because the animals were treated before ocular hypertension or before established DBA2J disease was documented, the experiments show preservation, not recovery, of already lost neurons.
00:17:02.639 --> 00:17:06.640
Could surviving retinal ganglion cells be dysfunctional before they die?
00:17:06.960 --> 00:17:07.599
Yes.
00:17:07.839 --> 00:17:11.359
That is a plausible and increasingly important view of glaucoma.
00:17:11.599 --> 00:17:17.039
Visual field loss does not require every affected retinal ganglion cell to have disappeared.
00:17:17.279 --> 00:17:25.920
A surviving cell may be present but have impaired energy supply, damaged dendrites, disrupted synapses, or a failing connection to the brain.
00:17:26.160 --> 00:17:30.000
The October study gives two pieces of evidence
consistent with this idea.
00:17:30.240 --> 00:17:43.359
In the ACAP1 deficient mice, exposed to ocular hypertension, pattern electroretinogram amplitude was worse even though retinal ganglion cell counts were not significantly lower than in pressure-stressed wild-type mice.
00:17:43.680 --> 00:17:50.640
In DBA2J glaucoma, ACAC1 treatment improved electrical responses alongside structural protection.
00:17:50.880 --> 00:17:53.839
The first finding is suggestive, not definitive.
00:17:54.079 --> 00:18:04.160
The knockout animals had a small but statistically significant pressure difference, and the retinal cell count analysis may not have been powered to detect a modest additional loss.
00:18:04.400 --> 00:18:10.400
The authors also note that lifelong ACAT-1 deficiency could prompt developmental compensation.
00:18:10.799 --> 00:18:13.920
This fits a broader concept of functional reserve.
00:18:14.160 --> 00:18:19.279
An eye can have more dysfunction than the number of visibly lost cells alone would predict.
00:18:19.519 --> 00:18:27.920
Mitochondrial dysfunction could contribute to that reserve by leaving living neurons short of energy or less able to sustain synaptic signaling.
00:18:28.079 --> 00:18:37.440
But this study did not determine what fraction of human visual field loss is reversible mitochondrial dysfunction rather than irreversible loss of cells and axons.
00:18:37.759 --> 00:18:40.559
Could mitochondrial treatment restore function?
00:18:41.519 --> 00:18:49.519
It is biologically plausible that improving energy supply might improve the performance of stressed but living retinal ganglion cells.
00:18:49.759 --> 00:18:58.480
That possibility is different from regenerating dead cells, restoring lost optic nerve axons, or rebuilding disconnected brain circuits.
00:18:58.720 --> 00:19:03.119
The study does not show that ACAT-1 restored existing synaptic function.
00:19:03.279 --> 00:19:07.759
It measured better endpoint responses in animals treated before pressure injury.
00:19:07.920 --> 00:19:14.319
There was no documented stage in which animals first developed impaired visual responses and were then treated.
00:19:14.480 --> 00:19:24.559
Thus, function improved in the treated groups should be read as better function than in untreated glaucoma controls, not as proven recovery from a known pretreatment deficit.
00:19:24.799 --> 00:19:28.880
Did the experiments test treatment after glaucoma was established?
00:19:29.200 --> 00:19:29.519
No.
00:19:29.920 --> 00:19:34.240
The main intervention experiments were preventive or early intervention designs.
00:19:34.559 --> 00:19:45.359
DBES2J mice, the vector was injected at five months, while the model's pressure elevation typically begins around five to seven months and damage becomes marked later.
00:19:45.599 --> 00:19:48.400
The study assessed the animals at 10 months.
00:19:48.640 --> 00:19:54.960
The treatment was therefore given before advanced disease and may have preceded measurable injury in many animals.
00:19:55.279 --> 00:20:00.880
Microbead model, vector was given three weeks before bead-induced pressure elevation.
00:20:01.599 --> 00:20:07.359
Cell cultures, cells were transduced before exposure to pressure or paraquat stress.
00:20:07.519 --> 00:20:16.880
The study did not test ACAP-1 restoration after documented retinal ganglion cell dysfunction, after measured cell loss, or after loss of axonal transport.
00:20:17.039 --> 00:20:19.440
It did not demonstrate axonal regrowth.
00:20:19.680 --> 00:20:32.960
The authors measured cholerotoxin B labeling in the superior colliculus, which is a useful proxy for transport and projection integrity, but not proof of regenerated axons or restored functional synapses in the brain.
00:20:33.200 --> 00:20:43.519
Practical implication ACAP1 currently looks more like a candidate for slowing or preventing deterioration than a proven way to recover vision in established glaucoma.
00:20:44.000 --> 00:20:47.920
How viable is AAV2 delivery to human retinal ganglion cells?
00:20:48.240 --> 00:20:58.880
Adeno-associated virus serotype 2 is a plausible delivery vehicle for retinal ganglion cells, and intravitrial gene delivery has been tested clinically in optic nerve disease.
00:20:59.119 --> 00:21:08.640
But AAV2 is used in eye gene therapy does not mean that every intravitrial AAV2 construct will efficiently reach every human retinal ganglion cell.
00:21:08.799 --> 00:21:15.519
Delivery depends on dose, vector design, the retinal surface barriers, and individual immune responses.
00:21:15.839 --> 00:21:19.680
Pre-existing neutralizing antibodies can reduce transduction.
00:21:19.920 --> 00:21:26.480
Intravitrial vectors can also trigger inflammation, and immune responses may become more likely as dose increases.
00:21:26.640 --> 00:21:31.680
After an initial injection, the body may make antibodies that make another dose less effective.
00:21:32.000 --> 00:21:35.839
Review of ocular adenoassociated virus delivery barriers.
00:21:36.079 --> 00:21:39.599
Study of human immune responses after intravitreal AAV2.
00:21:39.920 --> 00:21:46.240
The new ACAT1 experiment used a mouse vector carrying mouse AKHAT1 and a broad promoter.
00:21:46.400 --> 00:21:56.640
It does not establish the best human dose, the best promoter, whether expression should be limited to retinal ganglion cells, or how long expression remains safe and effective.
00:21:56.880 --> 00:21:59.599
The researchers also did not conduct long term follow up.
00:22:00.160 --> 00:22:02.799
Sufficient to show how durable the protection would be.
00:22:03.039 --> 00:22:06.640
Permanent overexpression deserves particular caution.
00:22:06.960 --> 00:22:13.519
Mitochondrial fission has normal roles in transport, quality control, and removal of damaged mitochondria.
00:22:13.920 --> 00:22:22.079
A strong, lifelong push toward fusion could conceivably interfere with those processes or with mitochondrial movement along long axons.
00:22:22.319 --> 00:22:29.440
The study did not show that overexpression caused harm, but it also did not establish a safe long-term expression range.
00:22:29.680 --> 00:22:36.799
A dose response study and prolonged safety monitoring are needed before more ACAP1 can be assumed to be better.
00:22:37.119 --> 00:22:39.759
Could medicines target the same pathway?
00:22:40.000 --> 00:22:51.519
Several of the options named in the prompt have some connection to energy metabolism, mitochondrial quality control, or neuronal survival that does not make them substitutes for ACAP1 restoration.
00:22:51.839 --> 00:23:03.680
To claim that a drug acts like ACAP1, researchers would need to show that it changes the relevant pathway in retinal ganglion cells at an achievable retinal dose and improves meaningful glaucoma outcomes.
00:23:03.920 --> 00:23:08.160
For the full table, please open this article on VisualFieldTest.com.
00:23:08.400 --> 00:23:19.359
For example, DRP1 inhibition and DV1 have been investigated in experimental pressure injury, but that is preclinical evidence, not a clinically available glaucoma treatment.
00:23:19.599 --> 00:23:23.200
Nicotinamide has moved further into human research.
00:23:23.599 --> 00:23:33.039
Small studies have reported functional signals, and a phase 3 trial of nicotinamide and pyruvate was designed to test longer-term outcomes.
00:23:33.279 --> 00:23:44.799
The American Glaucoma Society and American Academy of Ophthalmology have cautioned that high-dose nicotinamide should be limited to supervised clinical trials because of potential liver toxicity.
00:23:45.039 --> 00:23:55.279
Preclinical DRP1 inhibition study, Phase III nicotinamide and pyruvate trial design, American Glaucoma Society and American Academy of Ophthalmology guidance.
00:23:55.519 --> 00:24:07.119
Bottom line on medicines No currently established drug has been shown to reproduce the full ACAP1 pKa DRP1 OPA1 response in the human retina at a proven therapeutic exposure.
00:24:07.359 --> 00:24:11.039
How ACAP 1 compares with other neuroprotective approaches.
00:24:11.279 --> 00:24:13.519
These are not all the same kind of treatment.
00:24:13.680 --> 00:24:19.039
Some aim to protect surviving cells, others aim to improve cell function or regrow axons.
00:24:19.200 --> 00:24:23.279
The table separates human development maturity from biological promise.
00:24:23.519 --> 00:24:27.759
For the full table, please open this article on VisualFieldtest.com.
00:24:28.079 --> 00:24:33.839
ASP 2767 information from a stellus G01 Phase II trial record.
00:24:34.160 --> 00:24:36.960
NT501 Phase 1 glaucoma study.
00:24:37.279 --> 00:24:40.559
Life Biosciences October 8th ER100 Update.
00:24:40.720 --> 00:24:43.039
POU2F2 Optic Nerve Crush Study.
00:24:43.200 --> 00:24:46.799
NIH Summary of Calcium Calmodulin-dependent Kinase II Research.
00:24:46.960 --> 00:24:48.799
Ranking by Human Development Maturity.
00:24:48.960 --> 00:24:52.799
Nicotinamide has the broadest human research base among these approaches.
00:24:53.119 --> 00:24:56.799
GRO1 and NT501 have phase 2 glaucoma studies.
00:24:57.039 --> 00:25:00.640
ASP2767 is in early human development.
00:25:00.960 --> 00:25:03.920
ER100 has early phase 1 observations.
00:25:04.160 --> 00:25:09.200
AK1 restoration and POU2F2 remain preclinical for glaucoma.
00:25:09.680 --> 00:25:12.319
Ranking by potential to restore damaged function.
00:25:12.559 --> 00:25:18.559
ER-100 and nerve growth factor approaches are explicitly aimed at supporting or rejuvenating surviving cells.
00:25:18.799 --> 00:25:24.880
AK1 has a credible energy and synapse rationale, but has not yet been tested after dysfunction begins.
00:25:25.119 --> 00:25:33.519
Po2F2 is notable for axon regeneration results after optic nerve crush, but that is not the same as chronic human glaucoma.
00:25:33.839 --> 00:25:37.599
None can restore retinal ganglion cells that have already died.
00:25:37.839 --> 00:25:42.319
What experiment would show whether ACAT1 can rescue established glaucoma?
00:25:42.640 --> 00:25:49.920
The most convincing next experiment would deliberately wait until each animal has documented functional decline before treatment.
00:25:50.240 --> 00:25:53.279
Induce ocular hypertension in a glaucoma model.
00:25:53.440 --> 00:26:02.799
Measure pressure repeatedly and record a baseline pattern electroretinogram, visual evoked potential, retinal nerve fiber structure, and retinal ganglion cell integrity.
00:26:03.039 --> 00:26:09.039
Enroll only animals with a pre-specified measurable functional deficit before end-stage cell loss.
00:26:09.279 --> 00:26:14.319
Randomize them to ACAP1 vector, null vector, and an appropriate sham or control group.
00:26:14.480 --> 00:26:21.680
Blind investigators measuring pressure, visual function, structure, tracer transport, and tissue outcomes.
00:26:22.000 --> 00:26:29.359
Match or model cumulative pressure exposure rather than relying only on a non-significant difference in average readings.
00:26:29.920 --> 00:26:34.880
Follow the animals long enough to distinguish a temporary change from durable protection.
00:26:35.359 --> 00:26:46.480
Directly measure mitochondrial respiration and cellular adenosine triphosphate where possible and test whether blocking the proposed DRP1 or PKA mechanism removes the benefit.
00:26:46.720 --> 00:26:56.880
Include a second cohort treated after documented retinal ganglion cell loss to determine whether the therapy has any capacity beyond protecting remaining neurons.
00:26:57.119 --> 00:27:12.240
The decisive result would be a sustained improvement from each animal's own impaired pretreatment baseline without a pressure reduction, accompanied by evidence that the same previously impaired retinal ganglion cells remain alive and function better.
00:27:12.480 --> 00:27:20.319
If ACAP1 treated animals merely decline more slowly than controls, that would establish neuroprotection, not rescue.
00:27:20.480 -->
00:27:25.119
Could mitochondrial treatments become a real pressure-independent therapy?
00:27:25.440 --> 00:27:37.759
Fact, the October 2026 study shows that preventive ACAP-1 restoration protected retinal ganglion cells and visual risk measures in two mouse glaucoma models without a detected lowering of eye pressure.
00:27:38.000 --> 00:27:45.119
It also links treatment with improved mitochondrial measures, synaptic markers, and lower inflammatory markers.
00:27:45.599 --> 00:27:46.960
Strong inference.
00:27:47.200 --> 00:27:51.359
Mitochondrial resilience is a credible pressure-independent treatment target.
00:27:51.519 --> 00:27:56.559
It may help preserve both retinal ganglion cells and the function of cells that have not yet died.
00:27:56.720 --> 00:28:00.480
It would complement, not replace, pressure-lowering treatment.
00:28:01.119 --> 00:28:02.720
Inform speculation.
00:28:03.039 --> 00:28:09.200
ACAP-1 is likely to be part of human glaucoma biology, but it is unlikely to be the only driver.
00:28:09.440 --> 00:28:14.559
Its importance may vary between patients, stages of disease, and retinal cell types.
00:28:14.799 --> 00:28:23.839
A treatment that works best early before major cell and axon loss seems more plausible than one that restores advanced disconnected visual pathways.
00:28:24.160 --> 00:28:26.720
Estimated probabilities and timeline.
00:28:26.880 --> 00:28:30.720
These are judgment-based estimates, not published clinical trial probabilities.
00:28:30.880 --> 00:28:33.359
They are intended to make uncertainty explicit.
00:28:33.519 --> 00:28:39.839
Probability ACAT1 is genuinely important in human glaucomatous neurodegeneration, about 70%.
00:28:40.480 --> 00:28:45.440
The cell-specific human tissue signal and converging animal biology support relevance.
00:28:45.599 --> 00:28:50.319
Small human samples and uncertain causality keep the estimate well below certainty.
00:28:50.480 --> 00:29:00.480
Probability AAV2 ACAT1 works in a primate glaucoma model, about 50% for measurable target engagement plus at least one structural or functional benefit.
00:29:00.720 --> 00:29:03.119
Mouse results and AAV experience help.
00:29:03.279 --> 00:29:08.000
Species-specific delivery, dose, and immune response are major unknowns.
00:29:08.319 --> 00:29:14.880
Probability this specific pathway enters a human trial, about 35 to 40% by 2035.
00:29:15.200 --> 00:29:25.359
AAV retinal delivery is already a clinical modality, but this particular product still needs a suitable human construct, dose, safety studies, and large animal evidence.
00:29:25.599 --> 00:29:28.960
Probability it produces clinically meaningful neuroprotection.
00:29:29.200 --> 00:29:31.440
About 20% overall at this stage.
00:29:31.599 --> 00:29:40.319
The chance would rise if primate studies replicated the effect, and human trials showed slower progression on reliable structural and functional measures.
00:29:40.720 --> 00:29:46.079
Probability it recovers some function in stressed but surviving retinal ganglion cells.
00:29:46.319 --> 00:29:47.200
About 30%.
00:29:47.839 --> 00:29:55.279
The biology is plausible, and the mouse functional results are encouraging, but there is no treatment after dysfunction evidence yet.
00:29:55.519 --> 00:29:59.920
Earliest plausible first human trial, 2030 to 2032.
00:30:00.079 --> 00:30:07.839
Assuming a well-funded program and favorable large animal and toxicology results, a more ordinary path could take longer.
00:30:08.079 --> 00:30:15.759
Earliest plausible clinical availability, around 2038 if development proceeds unusually quickly and trials succeed.
00:30:16.000 --> 00:30:23.359
Availability in the early 2040s, or no approval at all, is more realistic than assuming a near-term treatment.
00:30:23.680 --> 00:30:28.160
The figures are estimates, not a forecast based on a completed development plan.
00:30:28.319 --> 00:30:32.240
The key near-term test is not another claim that mitochondria matter.
00:30:32.400 --> 00:30:40.319
It is whether ACAP1 can rescue established dysfunction while pressure is carefully matched and long-term safety is monitored.
00:30:40.559 --> 00:30:45.519
Could fixing mitochondria protect vision even when eye pressure is already low?
00:30:45.839 --> 00:30:46.640
Possibly.
00:30:46.880 --> 00:30:54.960
This study strengthens the case that protecting retinal energy systems could slow vision loss even when treatment does not lower eye pressure.
00:30:55.200 --> 00:31:04.160
It does not yet show that ACAP1 can restore vision after established glaucoma damage, and it provides no basis for stopping pressure-lowering treatment.
00:31:04.400 --> 00:31:10.880
For now, mitochondrial resilience is a promising research direction, not a proven treatment.
00:31:11.200 --> 00:31:14.960
All links to sources are available in the text version of this article.
00:31:15.119 --> 00:31:18.720
You can find the full article at VisualFieldTest.com.
00:31:18.960 --> 00:31:20.079
Thanks for listening.
00:31:20.240 --> 00:31:26.079
To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.